AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30531573 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical ablation
Number of subjects: 147
Study 30532779 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 43
Study 30532779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 43
Study 30534007 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg or 20 mg, bodyweight-adjusted, single-dose)
Number of subjects: 59
Study 30534008 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 59
Study 30534008 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 59
Study 30534008 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (tablet and oral suspension)
Number of subjects: 59
Study 30534152 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS)
Number of subjects: 32
Study 30534152 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 32
Study 30534187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil omega-3 (3.17 g per day; eicosapentaenoic acid 2.15 g; docosahexaenoic acid 1.02 g)
Number of subjects: 282
Study 30534187 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil
Number of subjects: 282
Study 30534187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil omega-3
Number of subjects: 282
Study 30534341 — intervention group
Group type: EXPERIMENTAL
Intervention: TRACK questionnaire (Portuguese version)
Number of subjects: 299
Study 30534340 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust from allergic subjects
Number of subjects: 50
Study 30534340 — intervention group
Group type: COMPARATOR
Intervention: House dust from non-allergic subjects
Number of subjects: 50
Study 30534374 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg once daily
Number of subjects: 130
Study 30534374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 30535053 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care models that integrate comorbidities, mainly via transdiagnostic self-management support, interprofessional collaboration, and digital approaches for treatment, monitoring, and communication.
Number of subjects: 39
Study 30535053 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care models targeting depressive disorders and other comorbid conditions.
Number of subjects: 39
Study 30535053 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care models in primary care.
Number of subjects: 39
Study 30535067 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic risk score
Number of subjects: 1313
Study 30535067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition pathways
Number of subjects: 1313
Study 30535067 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition-related pathways
Number of subjects: 1313
Study 30535067 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocal causation
Number of subjects: 1313
Study 30535087 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of plasma TMAO concentration
Number of subjects: 1718
Study 30535087 — intervention group
Group type: EXPERIMENTAL
Intervention: Each SD increment of ln-transformed plasma TMAO
Number of subjects: 1718
Study 30535190 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftaroline 600 mg as a 1 h intravenous infusion
Number of subjects: 9
Study 30535367 — intervention group
Group type: EXPERIMENTAL
Intervention: Ottawa AF cardioversion protocol (OAFCP)
Number of subjects: 889
Study 30535367 — intervention group
Group type: COMPARATOR
Intervention: Standard cardioversion protocol (Phase I)
Number of subjects: 889
Study 30535387 — intervention group
Group type: EXPERIMENTAL
Intervention: IBDoc home-based fecal calprotectin (FC) measuring test
Number of subjects: 61
Study 30535795 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice intake
Number of subjects: 45411
Study 30535795 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing rice with noodles
Number of subjects: 45411
Study 30535795 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing rice with red meat
Number of subjects: 45411
Study 30535795 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing rice with poultry
Number of subjects: 45411
Study 30535795 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing rice with white bread
Number of subjects: 45411
Study 30535795 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing rice with wholemeal bread
Number of subjects: 45411
Study 30536725 — intervention group
Group type: EXPERIMENTAL
Intervention: G-AgP
Number of subjects: 87
Study 30536725 — intervention group
Group type: EXPERIMENTAL
Intervention: CP
Number of subjects: 87
Study 30536725 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingivitis
Number of subjects: 87
Study 30536725 — intervention group
Group type: COMPARATOR
Intervention: Healthy
Number of subjects: 87
Study 30536810 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab
Number of subjects: 0
Study 30536931 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Scientific LATITUDE RPM system
Number of subjects: 300
Study 30536931 — intervention group
Group type: EXPERIMENTAL
Intervention: RPM preference
Number of subjects: 300
Study 30536931 — intervention group
Group type: EXPERIMENTAL
Intervention: In-clinic follow-up preference
Number of subjects: 300
Study 30536931 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education, employment, new LATITUDE model
Number of subjects: 300
Study 30536931 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease
Number of subjects: 300
Study 30537010 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor TLR9 rs352139 AG/GG carriers
Number of subjects: 297
Study 30537010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of donor CYP3A5 rs776746 and donor TLR9 rs352139 genotypes
Number of subjects: 297
Study 30537010 — intervention group
Group type: EXPERIMENTAL
Intervention: AG/GG patients
Number of subjects: 297
Study 30537170 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 144
Study 30537170 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) with diabetes remission
Number of subjects: 144
Study 30537170 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) without diabetes remission
Number of subjects: 144
Study 30537170 — intervention group
Group type: COMPARATOR
Intervention: Non-operated controls
Number of subjects: 144
Study 30537529 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (loading dose of 1.8 mg/m)
Number of subjects: 3
Study 30537545 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 μg vitamin D oral bolus
Number of subjects: 0
Study 30537548 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal vein embolization (PVE)
Number of subjects: 128
Study 30537548 — intervention group
Group type: COMPARATOR
Intervention: No portal vein embolization (NoPVE)
Number of subjects: 128
Study 30537877 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions with biological and nonbiological network members regarding risk information and management strategies.
Number of subjects: 0
Study 30537877 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactions with nonbiological network members.
Number of subjects: 0
Study 30537968 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) gel for 1 hour daily for 3 weeks
Number of subjects: 58
Study 30537968 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide (CP) gel
Number of subjects: 58
Study 30537991 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Number of subjects: 179
Study 30537991 — intervention group
Group type: COMPARATOR
Intervention: Topotecan
Number of subjects: 179
Study 30538057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin/rivaroxaban co-therapy
Number of subjects: 9954
Study 30538057 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS-Like patients
Number of subjects: 9954
Study 30538057 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS-Excluded patients
Number of subjects: 9954
Study 30538057 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS enrichment criteria
Number of subjects: 9954
Study 30538102 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-field OCTA
Number of subjects: 88
Study 30538161 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hour E-test approach
Number of subjects: 28
Study 30538161 — intervention group
Group type: COMPARATOR
Intervention: Standard routine methods
Number of subjects: 28
Study 30538817 — intervention group
Group type: EXPERIMENTAL
Intervention: Anifrolumab treatment
Number of subjects: 0
Study 30538817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30538854 — intervention group
Group type: EXPERIMENTAL
Intervention: TPRK (Transepithelial Photorefractive Keratectomy)
Number of subjects: 100
Study 30538854 — intervention group
Group type: COMPARATOR
Intervention: AAPRK (Alcohol-Assisted Photorefractive Keratectomy)
Number of subjects: 100
Study 30538968 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad:MG1 oncolytic vaccination strategy
Number of subjects: 0
Study 30538968 — intervention group
Group type: COMPARATOR
Intervention: Ad vaccine
Number of subjects: 0
Study 30538968 — intervention group
Group type: EXPERIMENTAL
Intervention: MG1 vaccine
Number of subjects: 0
Study 30538975 — intervention group
Group type: EXPERIMENTAL
Intervention: Resuscitation with the placental circulation intact
Number of subjects: 0
Study 30538975 — intervention group
Group type: COMPARATOR
Intervention: Cord milking
Number of subjects: 0
Study 30539362 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Number of subjects: 0
Study 30539492 — intervention group
Group type: COMPARATOR
Intervention: Locoregional treatment (LRT) including radiotherapy, surgery, or both
Number of subjects: 4276
Study 30539492 — intervention group
Group type: COMPARATOR
Intervention: Locoregional treatment (LRT)
Number of subjects: 4276
Study 30539524 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoBarrier™ implantation
Number of subjects: 10
Study 30540612 — intervention group
Group type: COMPARATOR
Intervention: Prefrail patients
Number of subjects: 133
Study 30540612 — intervention group
Group type: COMPARATOR
Intervention: Frail patients
Number of subjects: 133
Study 30540612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfrail patients
Number of subjects: 133
Study 30540645 — intervention group
Group type: EXPERIMENTAL
Intervention: ST-2 levels greater than 54 ng/ml
Number of subjects: 121
Study 30540645 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP levels greater than 567 pg/ml
Number of subjects: 121
Study 30540645 — intervention group
Group type: COMPARATOR
Intervention: Serum ST-2 levels in diabetic patients
Number of subjects: 121
Study 30540645 — intervention group
Group type: COMPARATOR
Intervention: BNP levels in HFrEF vs HFpEF
Number of subjects: 121
Study 30540645 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ST-2 and BNP in diabetic patients
Number of subjects: 121
Study 30540645 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ST-2 and left ventricular stiffness in diabetic patients
Number of subjects: 121
Study 30540648 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 13980
Study 30540702 — intervention group
Group type: EXPERIMENTAL
Intervention: Analytic focused health information
Number of subjects: 52
Study 30540702 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion focused health information
Number of subjects: 52
Study 30540702 — intervention group
Group type: EXPERIMENTAL
Intervention: Both analytic and emotional information
Number of subjects: 52
Study 30541333 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeCourse (LC) program delivered by community health workers (CHWs) with standardized monthly 1-hour home visits based on palliative care guidelines and motivational interviewing.
Number of subjects: 903
Study 30541333 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeCourse (LC) program
Number of subjects: 903
Study 30541333 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 903
Study 30541456 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 431
Study 30541456 — intervention group
Group type: COMPARATOR
Intervention: Non-black race
Number of subjects: 431
Study 30541456 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 431
Study 30541457 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual histology intravascular ultrasound (VH-IVUS) assessment of plaque composition and characteristics
Number of subjects: 175
Study 30541505 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care testing for procalcitonin (PCT) using 0.5 ml of whole blood; results available within 20 minutes.
Number of subjects: 126
Study 30541560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound during antenatal care (ANC)
Number of subjects: 700
Study 30541560 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication strategies (referral card, directions, expectations)
Number of subjects: 700
Study 30541560 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to attending referrals
Number of subjects: 700
Study 30541560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening at ANC
Number of subjects: 700
Study 30541571 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner Syndrome
Number of subjects: 57
Study 30541571 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner Syndrome with coarctation
Number of subjects: 57
Study 30541571 — intervention group
Group type: EXPERIMENTAL
Intervention: Turner Syndrome without coarctation
Number of subjects: 57
Study 30541757 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning surgery (8:00 to 11:00)
Number of subjects: 630
Study 30541757 — intervention group
Group type: COMPARATOR
Intervention: Afternoon surgery (14:00 to 17:00)
Number of subjects: 630
Study 30541757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (morning and afternoon)
Number of subjects: 630
Study 30542286 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ)
Number of subjects: 0
Study 30542289 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-periodized (NP) resistance training
Number of subjects: 42
Study 30542289 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily undulating periodization (DUP) resistance training
Number of subjects: 42
Study 30542289 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 42
Study 30542319 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30542322 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH measured using Elecsys® AMH automated assay
Number of subjects: 22
Study 30542322 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH measured at the moment of LH rise
Number of subjects: 22
Study 30542377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of everolimus, lapatinib, and capecitabine
Number of subjects: 19
Study 30542622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin sodium (initial dose of 5000 IU, adjustable by 500 or 1000 IU increments)
Number of subjects: 152
Study 30542662 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening, prevention and care for tuberculosis and HIV
Number of subjects: 0
Study 30542662 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30543050 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin-releasing peptide receptor antagonist
Number of subjects: 0
Study 30543347 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 400 mg once daily plus fulvestrant 500 mg
Number of subjects: 87
Study 30543347 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 to 400 mg once daily plus fulvestrant
Number of subjects: 87
Study 30543347 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg once daily plus fulvestrant
Number of subjects: 87
Study 30543456 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with interstitial lung abnormalities (ILA) in COPDGene
Number of subjects: 7923
Study 30543456 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with interstitial lung abnormalities (ILA) in ECLIPSE
Number of subjects: 7923
Study 30543456 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with interstitial lung abnormalities (ILA) in FHS
Number of subjects: 7923
Study 30543456 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with idiopathic pulmonary fibrosis (IPF)
Number of subjects: 7923
Study 30543456 — intervention group
Group type: EXPERIMENTAL
Intervention: Research participants with ILA
Number of subjects: 7923
Study 30543557 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective minor abdominal surgery
Number of subjects: 60
Study 30544060 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront DPYD-guided dose individualisation with initial dose reduction of 25% or 50% based on DPYD variants screening.
Number of subjects: 0
Study 30544060 — intervention group
Group type: COMPARATOR
Intervention: No DPYD screening (control group).
Number of subjects: 0
Study 30544060 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront DPYD-guided dose individualisation.
Number of subjects: 0
Study 30544235 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with PCOS
Number of subjects: 20
Study 30544235 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 20
Study 30545622 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT-based strategies
Number of subjects: 3696
Study 30545622 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-based strategies
Number of subjects: 3696
Study 30545622 — intervention group
Group type: EXPERIMENTAL
Intervention: LoD-algorithm
Number of subjects: 3696
Study 30545622 — intervention group
Group type: COMPARATOR
Intervention: Dual-marker approach
Number of subjects: 3696
Study 30545622 — intervention group
Group type: COMPARATOR
Intervention: NICE-algorithm using hs-cTnI
Number of subjects: 3696
Study 30545672 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum uric acid (SUA) levels
Number of subjects: 17913
Study 30545809 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective para-aortic radiotherapy (PART)
Number of subjects: 137
Study 30545809 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant whole pelvic radiotherapy (WPRT) alone
Number of subjects: 137
Study 30545813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating training (12-week group intervention)
Number of subjects: 60
Study 30545813 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted diet with mindful eating training
Number of subjects: 60
Study 30545813 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-restricted diet without mindful eating training
Number of subjects: 60
Study 30545813 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating training
Number of subjects: 60
Study 30546043 — intervention group
Group type: EXPERIMENTAL
Intervention: Late AKI
Number of subjects: 2152
Study 30546947 — intervention group
Group type: EXPERIMENTAL
Intervention: MAGE-A3 vaccination utilizing the oncolytic Maraba virus
Number of subjects: 0
Study 30546948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 30546948 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in selective adjuvant combinations
Number of subjects: 0
Study 30546962 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab in conjunction with chemotherapy
Number of subjects: 0
Study 30546962 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolbetuximab
Number of subjects: 0
Study 30546962 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0
Study 30547094 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal thickness measurement
Number of subjects: 0
Study 30547379 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-injector (AI)
Number of subjects: 265
Study 30547379 — intervention group
Group type: COMPARATOR
Intervention: Pre-filled syringe (PFS)
Number of subjects: 265
Study 30547388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime fast-acting insulin aspart (faster aspart)
Number of subjects: 1686
Study 30547388 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IAsp) or basal-only insulin therapy
Number of subjects: 1686
Study 30547388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart
Number of subjects: 1686
Study 30547388 — intervention group
Group type: COMPARATOR
Intervention: Insulin comparators
Number of subjects: 1686
Study 30547830 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive foetal RHD genotyping
Number of subjects: 850
Study 30547830 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 850
Study 30548089 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Mellitus (DM) status in patients with HFrEF
Number of subjects: 5255
Study 30548089 — intervention group
Group type: EXPERIMENTAL
Intervention: Asian women with HFrEF
Number of subjects: 5255
Study 30548089 — intervention group
Group type: COMPARATOR
Intervention: Asian men with HFrEF
Number of subjects: 5255
Study 30548235 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 50 years
Number of subjects: 547
Study 30548235 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking for more than 0 pack-years
Number of subjects: 547
Study 30548235 — intervention group
Group type: EXPERIMENTAL
Intervention: N3 disease
Number of subjects: 547
Study 30548235 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 disease
Number of subjects: 547
Study 30548235 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative p16 status
Number of subjects: 547
Study 30548438 — intervention group
Group type: EXPERIMENTAL
Intervention: AVXS-101 gene replacement therapy
Number of subjects: 12
Study 30549051 — intervention group
Group type: EXPERIMENTAL
Intervention: Epistaxis patients (n=41)
Number of subjects: 82
Study 30549051 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (n=41)
Number of subjects: 82
Study 30549051 — intervention group
Group type: EXPERIMENTAL
Intervention: Study population (n=82)
Number of subjects: 82
Study 30549418 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pelvic nerve crush injury (BPNI)
Number of subjects: 0